Nasdaq
$14.51▼ 1.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.68BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 10.1Pre-market26.10.01 22:008-KKey event#●●●#●●●#●●●
NovoCure LtdBullish
Novocure's medical device 'Optune Pax' has received approval from Japan's Ministry of Health, Labour and Welfare for the treatment of unresectable locally advanced pancreatic cancer. The approval is based on positive results from the Phase 3 PANOVA-3 clinical trial, marking a significant milestone for the company's expansion in the Japanese oncology market.…more
$14.51-1.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9Pre-market26.09.09 20:028-KKey event
NovoCure Ltd
Timothy Scannell, a member of the Board of Directors at NovoCure Limited, retired from his position effective September 2, 2026. The company confirmed that his departure followed five years of service and was not due to any disagreement with the company or its management.…more
$14.51-1.12%vs prev closeView filingShare - 9.1Pre-market26.09.01 20:008-KKey event
NovoCure Ltd
NovoCure identified unauthorized access to its information systems in mid-August 2026 and activated its cybersecurity response plan. The incident resulted in the exposure of internal ID numbers for over 1,400 U.S. patients, personal data for fewer than 50 patients, and contact information for healthcare providers and employees, though medical device operations remain unaffected. The company currently does not expect this incident to have a material impact on its financial condition or results of operations.…more
$14.51-1.12%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Pre-market26.10.01 22:04Bullish#●●●#●●●
Novocure Receives MHLW Approval for Optune Pax in Japan
Novocure's Optune Pax has been approved by Japan's Ministry of Health, Labour and Welfare for treating unresectable locally advanced pancreatic cancer. The device is indicated for use in combination with gemcitabine and nab-paclitaxel in adult patients.…more
$14.51-1.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.1Pre-market26.09.01 20:05
●●●●●●●● ●●●●● ●●●●●●
Novocure reported that unauthorized system access in mid-August exposed internal ID numbers for over 1,400 U.S. patients. The company confirmed that medical devices were not compromised and that operations remain fully functional.…more
$14.51-1.12%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report